ARG2 and neuroblastoma: Despite the success of immune checkpoint inhibitors in treating highly immunogenic adult solid tumors, they have not proven effective for NB patients due to factors such as low tumor mutation burden, limited MHC-I expression, infiltration by suppressive myeloid cells, and the production of inhibitory factors like arginase-2 and TGFβ [42–49].